Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Anton Pottegård und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Gabapentin, Practice Patterns, Physicians', Pregabalin, Drug Utilization. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Pregabalin and gabapentin are increasingly used for pain and other conditions. Concerns exist about overuse as well as potential misuse and abuse. To guide rational prescribing practices, we provide detailed nationwide data on the use of gabapentinoids in Denmark.
Methods
We conducted a nationwide descriptive drug utilization study using the Danish healthcare registries to describe the use of gabapentinoids among Danish adults 2010–2023. We described overall use patterns, temporal trends, user characteristics, skewness of use, treatment duration and concomitant medication use.
Results
The prevalence of gabapentinoid use increased almost four‐fold from 11 per 1000 adults in 2010 to 41 in 2023 with the highest use among individuals aged 80+ years (96 per 1000 in 2023). Gabapentin and pregabalin were used equally. The median age of users increased from 58 years in 2010 to 63 years in 2023, while a decline was observed in the proportion with concomitant use of other drug classes, including benzodiazepines or opioids. Only 7% of patients were continuously treated for 3 years following initiation, while 22% were currently treated after 3 years (allowing treatment breaks). The use of gabapentinoids were somewhat skewed with 1% of users accounting for 7.3% of use in 2023.
Conclusion
The use of gabapentinoids has increased dramatically in recent years, in particular, among the elderly, and adherence was low. Increased attention to the increasing use of gabapentinoids is warranted to ensure rational use of this drug class.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Centre for Public Health, Queen's University Belfast, Belfast, N, Ireland.
ORCID-Profile: Anton Pottegård, Lotte Rasmussen, Blánaid Hicks
Zitieren
APA
Pottegård, A., Rasmussen, L., Olesen, M., Skov Sørensen, A. M., Ennis, Z. N., Kane, J., Baxter, S., & Hicks, B. (2025). Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70060
Vancouver
Pottegård A, Rasmussen L, Olesen M, Skov Sørensen AM, Ennis ZN, Kane J, et al. Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70060
BibTeX
@article{Pottegrd2025,
author = {Pottegård, Anton and Rasmussen, Lotte and Olesen, Morten and Skov Sørensen, Anne Mette and Ennis, Zandra Nymand and Kane, Joseph and Baxter, Sarah and Hicks, Blánaid},
title = {Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70060}
}
EUVIMED